JP2025510339A5 - - Google Patents
Info
- Publication number
- JP2025510339A5 JP2025510339A5 JP2024557582A JP2024557582A JP2025510339A5 JP 2025510339 A5 JP2025510339 A5 JP 2025510339A5 JP 2024557582 A JP2024557582 A JP 2024557582A JP 2024557582 A JP2024557582 A JP 2024557582A JP 2025510339 A5 JP2025510339 A5 JP 2025510339A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- composition
- use according
- modified
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263324531P | 2022-03-28 | 2022-03-28 | |
| US63/324,531 | 2022-03-28 | ||
| US202263335152P | 2022-04-26 | 2022-04-26 | |
| US63/335,152 | 2022-04-26 | ||
| PCT/US2023/065074 WO2023192885A2 (en) | 2022-03-28 | 2023-03-28 | Methods of using oligomeric compounds to treat scn2a-related disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025510339A JP2025510339A (ja) | 2025-04-14 |
| JP2025510339A5 true JP2025510339A5 (enExample) | 2026-04-06 |
Family
ID=88203426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557582A Pending JP2025510339A (ja) | 2022-03-28 | 2023-03-28 | オリゴマー化合物を使用してｓｃｎ２ａ関連障害を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250179503A1 (enExample) |
| EP (1) | EP4499835A2 (enExample) |
| JP (1) | JP2025510339A (enExample) |
| AU (1) | AU2023244348A1 (enExample) |
| CA (1) | CA3246834A1 (enExample) |
| WO (1) | WO2023192885A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024343201A1 (en) * | 2023-09-15 | 2026-03-26 | Praxis Precision Medicines, Inc. | Elsunersen / prax-222 for use in the treatment of scn2a-related disorders |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8138201B2 (en) * | 2007-07-11 | 2012-03-20 | Medicinova, Inc. | Treatment of progressive neurodegenerative disease with ibudilast |
| IL297642A (en) * | 2020-04-29 | 2022-12-01 | Praxis Prec Medicines Inc | Methods for using t-type calcium channel modulators |
| IL300258A (en) * | 2020-08-07 | 2023-03-01 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating SCN2A |
-
2023
- 2023-03-28 WO PCT/US2023/065074 patent/WO2023192885A2/en not_active Ceased
- 2023-03-28 CA CA3246834A patent/CA3246834A1/en active Pending
- 2023-03-28 JP JP2024557582A patent/JP2025510339A/ja active Pending
- 2023-03-28 AU AU2023244348A patent/AU2023244348A1/en active Pending
- 2023-03-28 EP EP23782026.1A patent/EP4499835A2/en active Pending
- 2023-03-28 US US18/851,471 patent/US20250179503A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0850300B1 (en) | Method of modulating gene expression with reduced immunostimulatory response | |
| DE60132170T2 (de) | MODULIERUNG DER DURCH CpG-OLIGONUKLEOTIDE VERURSACHTEN IMMUNSTIMULIERUNG DURCH POSITIONSBEDINGTE VERÄNDERUNG VON NUKLEOSIDEN | |
| CA3099522C (en) | GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY | |
| DE69332206T2 (de) | Verwendung von oligonukleotiden mit einer konservierten g4-kernsequenz zur herstellung eines medikamentes | |
| JP5268214B2 (ja) | ヌクレオシドの位置的修飾によるオリゴヌクレオチドＣｐＧ−媒体免疫刺激の変調 | |
| JP7054675B2 (ja) | 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法 | |
| JP2020189874A (ja) | 状態および疾患の処置のためのアンチセンスオリゴマー | |
| CN111433361B (zh) | 天使综合征反义治疗 | |
| JP7836840B2 (ja) | 新規ｒｎａ治療法及びその使用 | |
| JP2021535204A5 (enExample) | ||
| JP2021072862A (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2021510511A5 (enExample) | ||
| JP2024534157A5 (enExample) | ||
| JP2025510339A5 (enExample) | ||
| US20110166197A1 (en) | Antisense Modulation Of Amyloid Beta Protein Expression | |
| US20240392301A1 (en) | Therapeutic uses and methods | |
| US20220296631A1 (en) | Methods for treating muscular dystrophy using inhibitory oligonucleotides to cd49d | |
| JP2021510512A5 (enExample) | ||
| JP2024536132A5 (enExample) | ||
| DE60117572T2 (de) | Inhibitoren der Reversen Transkriptase von HIV aus tRNA | |
| US20220090082A1 (en) | Gapmer antisense oligonucleotides targeting sars-cov-2 for treating covid 19 | |
| WO2026009916A1 (ja) | ２本鎖オリゴヌクレオチド | |
| WO2026044345A1 (en) | Methods and compositions for treatment of epilepsy | |
| JP2026509929A (ja) | 改善された遺伝子サイレンシングのための組成物及び方法 |